Representatives of in vitro diagnostics company EKF Diagnostics are exhibiting the company’s PointMan DNA-enrichment technology at the American Association of Cancer Research (AACR) conference this week.
According to company spokespersons, the product enables highly-specific cancer mutation detection and is an extremely sensitive and selective tool based on real-time PCR technology that offers the ability to enrich mutations from limited sample material. They are pointing out to attendees that this is vital for a companion diagnostic particularly in the field of oncology, where availability of tumor biopsy tissue is restricted. In collaboration with Swansea University, EKF Molecular is currently investigating the ability of PointMan kits to enrich mutant DNA from a blood-based sample. Initial results have demonstrated the detection of gene mutations in blood from samples archived in the Wales Cancer Bank.
PointMan DNA enrichment kits are available to detect a variety of mutations for cancer biomarkers including BRAF, KRAS, EGFR, NRAS, and JAK2. These genes are associated with skin melanoma, colorectal, and lung cancers, as well as myeloma. Learn more about EKF molecular diagnostics.
